• ElexoPharm GmbH, of Saarbruecken, Germany, named Chris van Koppen head of research.

• IntelliCell BioSciences Inc., of New York, appointed Robert Sexauer executive vice president and Sarah Young director of quality assurance.

• Iroko Pharmaceuticals LLC, of Philadelphia, named Clarence Young chief medical officer and Moji James general counsel and vice president.

• Jennerex Inc., of San Francisco, added Mitchell Gold to its board.

• Metabolic Solutions Development Co. LLC, of Kalamozoo, Mich., added Barbara Cannon to its science and medical advisory board.

• NeurOp Inc., of Atlanta, appointed Robert Zaczek chief scientific officer.

• Northwest Biotherapeutics, of Bethesda, Md., added Navid Malik and Jerry Jasinowski to its board.

• QLT Inc., of Vancouver, British Columbia, appointed Christopher Muller chief commercial officer.

• Repligen Corp., of Waltham, Mass., added Michael Griffith to its board.

• Sanguine BioSciences Inc., of Santa Monica, Calif., added Timothy Triche to its scientific advisory board.

• Selventa, of Cambridge, Mass., appointed William Hayes senior vice president of platform development.

• Syndax Pharmaceuticals Inc., of Waltham, Mass., appointed Arlene Morris CEO and Joanna Horobin president.

• Synthetic Biologics Inc., of Ann Arbor, Mich., named Michael Kaleko scientific director.

• TapImmune Inc., of Seattle, named Robert Florkiewicz senior director of molecular biology and virology.

• Transcept Pharmaceuticals Inc., of Point Richmond, Calif., appointed Thomas Soloway executive vice president and chief operating officer.

• Ultragenyx Inc., of Novato, Calif., named Shalini Sharp chief financial officer and senior vice president, finance, effective May 21.